| Literature DB >> 31825174 |
Yasuhiro Hamatani1,2, Isao Shiraishi3, Tatsuya Nishii4, Atsushi Okada1, Makoto Amaki1, Kizuku Yamasahita5, Yorihiko Matsumoto5, Hideaki Kanzaki1, Tetsuya Fukuda4, Tomoyuki Fujita5, Satoshi Yasuda1, Junjiro Kobayashi5, Chisato Izumi1.
Abstract
Surgical treatment is an effective therapy and the gold standard for patients with left ventricular outflow tract obstruction (LVOTO) and drug-refractory symptoms. However, it is difficult to arrange a concrete surgical plan due to the heterogenous and complex cardiac anatomy. Three-dimensional (3D) printing is an emerging technology that is able to reproduce complex cardiac anatomy. Here, we present two patients with LVOTO in whom we created 3D printed models. In these two patients, we compared the 3D printed model and the intraoperative findings and confirmed that the 3D printed model we created could reproduce the complex cardiac anatomy including the interventricular septum, papillary muscles, and abnormally thickened chordae. By using 3D printed models, cardiologists and surgeons can comprehend the complex 3D cardiac structure and spatial positional relationship preoperatively and perform surgical rehearsal. 3D printing could be a valuable tool for the management of patients with LVOTO.Entities:
Keywords: Left ventricular outflow tract obstruction; Multimodality imaging; Surgery; Three-dimensional printing
Mesh:
Year: 2019 PMID: 31825174 PMCID: PMC7083429 DOI: 10.1002/ehf2.12566
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
Characteristics of the patients with left ventricular outflow tract obstruction
| Case 1 | Case 2 | |
|---|---|---|
| <Backgrounds> | ||
| Age (years) | 73 | 57 |
| Sex | Female | Female |
| Symptom | Dyspnoea | Chest pain |
| NYHA functional class | III | II |
| Medications | Bisoprolol 5 mg, cibenzoline 150 mg | Bisoprolol 5 mg, verapamil 120 mg, cibenzoline 150 mg |
| B‐type natriuretic peptide (pg/mL) | 1216 | 35 |
| <Echocardiography> | ||
| Left ventricular ejection fraction (%) | 65 | 65 |
| Maximum wall thickness (mm) | 17 | 12 |
| Peak pressure gradient at rest (mmHg) | 144 | 73 |
| SAM of the mitral valve | — | — |
| Degree of mitral regurgitation | 1+ | 1+ |
| Abnormality of cardiac structure | Hypertrophied papillary muscle directly inserted into the mitral valve | Sub‐aortic stenosis and abnormally thickened chordae |
NYHA, New York Heart Association; SAM, systolic anterior motion.
Figure 1(A) Transthoracic echocardiography (parasternal long‐axis view). (B) Transesophageal echocardiography. (C) Contract‐enhanced computed tomography. (D, E) The 3D printed model of the patient. View across the mitral valve (D) and across the aortic valve (E). (F) The intraoperative finding across the aortic valve. AML, anterior mitral leaflet; Ao, aorta; AV, aortic valve; LA, left atrium; LCC, left coronary cusp; LV, left ventricle; MV, mitral valve; NCC, non‐coronary cusp; PM, papillary muscle; PML, posterior mitral leaflet; RCC, right coronary cusp.
Figure 2(A) Transthoracic echocardiography (apical five chamber view). (B) Transesophageal echocardiography. Sub‐aortic stenosis (blue arrow) was noted. (C) Contract‐enhanced computed tomography. Sub‐aortic stenosis (blue arrow) and the abnormally thickened chordae (yellow arrow) were noted. (D, E) The 3D printed model of the patient. Yellow arrow showed the thickened chordae and blue arrow showed the sub‐aortic stenosis. (F) The intraoperative finding across the aortic valve. Abnormal funicular structure (blue arrow) was confirmed. Ao, aorta; AV, aortic valve; LA, left atrium; LV, left ventricle; MV, mitral valve; RA, right atrium; RV, right ventricle.